Khartis Therapeutics has raised $50 million in a Series B funding round led by Forge Life Science Partners to advance its oral small molecule immunology pipeline.
PRIVATEAug 13, 2026
Amount Raised
$50 Million
Round Type
Series B
San DiegoBiotechnologyHealth CareTherapeutics
Investors
Nextech InvestLilly Asia VenturesForesite CapitalLongwood FundAlexandria Venture InvestmentsForge Life Science Partners
Description
Khartis Therapeutics, a biotechnology company, has emerged from stealth mode with a successful Series B financing round. The company raised $50 million to advance its development of oral small molecule medicines targeting immunological and chronic diseases. This funding round saw participation from notable investors such as Longwood Fund and Alexandria Venture Investments, along with existing supporters. The new capital will help propel the company's innovative pipeline forward.
Company Information
Company
Khartis Therapeutics
Location
San Diego, California, United States
About
Khartis Therapeutics is a biotechnology company focused on developing first- and best-in-class oral small molecule medicines aimed at treating immunological and chronic diseases. The company has recently emerged from stealth with significant funding to advance its innovative pipeline. Khartis is committed to transforming patient care through its unique therapeutic approach.
Fundz sees it the moment Khartis Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
San DiegoBiotechnologyHealth CareTherapeutics